Mark Melzer1, Irene Petersen. 1. Department of Microbiology, Queen's Hospital, Barking, Havering and Redbridge Trust, Romford, Essex, UK. mark.melzer@bhrhospitals.nhs.uk <mark.melzer@bhrhospitals.nhs.uk>
Abstract
OBJECTIVES: To determine the differences in mortality and length of hospital stay in patients with bacteraemic infection caused by ESBL and non-ESBL producing Escherichia coli. Main outcome measures were mortality, time from bacteraemia to death and length of inpatient stay. METHODS: From June 2003 to November 2005, we prospectively collected clinical and microbiological data on all adult patients with E. coli bacteraemia. RESULTS: ESBL producing E. coli caused 16/242 (6.6%) community-acquired and 30/112 (26.8%) hospital-acquired bacteraemic infections. The most common sites of infection were urine 239/354 (67.5%) and bile 41/354 (11.6%). All ESBL producers were resistant to cephalosporins. Resistance to ciprofloxacin, trimethoprim, gentamicin and amikacin were 42/46 (91.3%), 39/46 (84.8%), 14/46 (30.4%) and 2/46 (4.3%), respectively. A significantly higher proportion of patients died following a bacteraemic infection caused by ESBL producing E. coli, 28/46 (60.8%), compared to non-ESBL producing E. coli, 73/308 (23.7%). The adjusted odds ratio for death was 3.57 (95% CI 1.48-8.60, p<0.005). Delay in initiating an appropriate antibiotic was significantly associated with death and ESBL production. There was no significant difference between time from bacteraemia to death (median time 7 days (ESBL +ve group) vs 5 days (ESBL -ve group); p=0.69) and, in those who survived, length of inpatient stay (median time 9 days (ESBL +ve group) vs 12 days (ESBL -ve group); p=0.111). CONCLUSIONS: Mortality following bacteraemic infection caused by ESBL producing E. coli was significantly higher than non-ESBL producing E. coli. These findings have serious implications for antibiotic prescription, as cephalosporins are ineffective treatment for many E. coli infections.
OBJECTIVES: To determine the differences in mortality and length of hospital stay in patients with bacteraemic infection caused by ESBL and non-ESBL producing Escherichia coli. Main outcome measures were mortality, time from bacteraemia to death and length of inpatient stay. METHODS: From June 2003 to November 2005, we prospectively collected clinical and microbiological data on all adult patients with E. coli bacteraemia. RESULTS: ESBL producing E. coli caused 16/242 (6.6%) community-acquired and 30/112 (26.8%) hospital-acquired bacteraemic infections. The most common sites of infection were urine 239/354 (67.5%) and bile 41/354 (11.6%). All ESBL producers were resistant to cephalosporins. Resistance to ciprofloxacin, trimethoprim, gentamicin and amikacin were 42/46 (91.3%), 39/46 (84.8%), 14/46 (30.4%) and 2/46 (4.3%), respectively. A significantly higher proportion of patients died following a bacteraemic infection caused by ESBL producing E. coli, 28/46 (60.8%), compared to non-ESBL producing E. coli, 73/308 (23.7%). The adjusted odds ratio for death was 3.57 (95% CI 1.48-8.60, p<0.005). Delay in initiating an appropriate antibiotic was significantly associated with death and ESBL production. There was no significant difference between time from bacteraemia to death (median time 7 days (ESBL +ve group) vs 5 days (ESBL -ve group); p=0.69) and, in those who survived, length of inpatient stay (median time 9 days (ESBL +ve group) vs 12 days (ESBL -ve group); p=0.111). CONCLUSIONS: Mortality following bacteraemic infection caused by ESBL producing E. coli was significantly higher than non-ESBL producing E. coli. These findings have serious implications for antibiotic prescription, as cephalosporins are ineffective treatment for many E. coli infections.
Authors: B J Liss; J J Vehreschild; O A Cornely; M Hallek; G Fätkenheuer; H Wisplinghoff; H Seifert; M J G T Vehreschild Journal: Infection Date: 2012-06-05 Impact factor: 3.553
Authors: Vidhya Prakash; James S Lewis; Monica L Herrera; Brian L Wickes; James H Jorgensen Journal: Antimicrob Agents Chemother Date: 2009-01-05 Impact factor: 5.191
Authors: Erin K Sully; Bruce L Geller; Lixin Li; Christina M Moody; Stacey M Bailey; Amy L Moore; Michael Wong; Patrice Nordmann; Seth M Daly; Carolyn R Sturge; David E Greenberg Journal: J Antimicrob Chemother Date: 2017-03-01 Impact factor: 5.790
Authors: Tolbert Sonda; Happiness Kumburu; Marco van Zwetselaar; Michael Alifrangis; Blandina T Mmbaga; Ole Lund; Gibson S Kibiki; Frank M Aarestrup Journal: Eur J Clin Microbiol Infect Dis Date: 2018-07-20 Impact factor: 3.267
Authors: Dirk M Leinberger; Verena Grimm; Maya Rubtsova; Jan Weile; Klaus Schröppel; Thomas A Wichelhaus; Cornelius Knabbe; Rolf D Schmid; Till T Bachmann Journal: J Clin Microbiol Date: 2009-12-09 Impact factor: 5.948
Authors: Benjamin A Rogers; Paul R Ingram; Naomi Runnegar; Matthew C Pitman; Joshua T Freeman; Eugene Athan; Sally M Havers; Hanna E Sidjabat; Mark Jones; Earleen Gunning; Mary De Almeida; Kaylene Styles; David L Paterson Journal: Antimicrob Agents Chemother Date: 2014-01-27 Impact factor: 5.191